Analyst Price Target is $11.01
▲ +529.29% Upside Potential
This price target is based on 8 analysts offering 12 month price targets for Reneo Pharmaceuticals in the last 3 months. The average price target is $11.01, with a high forecast of $35.55 and a low forecast of $1.50. The average price target represents a 529.29% upside from the last price of $1.75.
Current Consensus is
Reduce
The current consensus among 8 investment analysts is to reduce stock in Reneo Pharmaceuticals. This Reduce consensus rating has held steady for over two years.
Reneo Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the development and commercialization of therapies for patients with rare genetic mitochondrial diseases. The company's lead product candidate is REN001, a potent and selective agonist of the peroxisome proliferator-activated receptor delta that is in clinical development for genetic mitochondrial diseases comprising primary mitochondrial myopathies and long-chain fatty acid oxidation disorders. Reneo Pharmaceuticals, Inc. was incorporated in 2014 and is headquartered in Irvine, California.
Read More